The Lancet· @TheLancet · X·· 2 天前评分90
正文 · 原文
Presenting at #ESMO2026—Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial https://spkl.io/60157kJtJ @myESMO
5097 浏览 · 14 赞 · 4 转发 · 0 回复
会议摘要
LBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.org来源：The Lancet · x.com